1.80 USD
▼-0.01-0.55%
盘后 2.11 0.00%
2026-09-16
市值
$12.64M
市盈率
—
EPS
-4.66
股息率
—
52 周区间
1.23 – 15.50
成交量
21.05K
Beta
—
目标价
—
52W 低 1.2352W 高 15.50
价格走势
公司简介
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.